TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00523302

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active TMS
Description: Active TMS uses the active TMS coil to stimulate the cortical area of interest. Active TMS involves 80 trains x 15 sec = 4000 pulses per session, 5 x per week= 20,000 pulses per week, x 2 weeks = 40,000 pulses.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS
Description: Sham TMS uses the same stimulation frequency as the Active TMS but uses the Sham TMS coil instead to prevent actual stimulation from occurring (chosen as a priori stimulation based on studies showing antidepressant and anti-nociceptive effects): 10 Hertz - Pulse train duration (on time) 5 seconds, Power (intensity) level 120% of stored motor threshold, Inter-train interval (off time) 10 seconds (15 second cycle time). Additionally, stimulation-train duration and inter-stimulus intervals were determined such that they are in compliance with current published rTMS safety guidelines.
Study: NCT04032093

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine
Description: RSV vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution for injection (0.9% sodium chloride injection)
Study: NCT01004991

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 on Day 8 of each of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m2 on Day 8 of each of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: 1.4 mg/m2 on Day 8 of each of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m2 on Day 8 of each of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg PO days 8-12 of each of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacytidine
Description: Dose level 1: azacytidine 25 mg/m2 days 1-5 Dose level 2: azacytidine 50 mg/m2 days 1-5 Dose level 3: azacytidine 75 mg/m2 days 1-5
Study: NCT02149043

Intervention type: DEVICE
Intervention: Thermography
Description: Thermographic imaging of the patient's abdomen surface

Intervention type: DEVICE
Intervention: Thermography
Description: Thermographic imaging of the patient's abdomen surface

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Endoscopic examination of the colon
Study: NCT02331888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scalp electrode, fetal doppler and EUM
Description: the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler.
Study: NCT04563949

Intervention type: OTHER
Intervention: Repeat Testing
Description: Repeat Testing with the PLA will be conducted
Study: NCT04691076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol is administered by target-controlled infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol is administered by target-controlled infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine is intravenously administrated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl is intravenously administrated
Study: NCT01730482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] AT1001
Description: 150 mg of \[14C\] labelled AT1001 will be administered as a solution (prepared by weighing 150 mg of AT1001 powder and dissolving in 100 mL of water). The entire solution will be swallowed orally. After ingestion of study medication, the dosing bottle will be rinsed with 50 mL of water and this will be ingested by the subject. This rinse procedure should be performed twice. Following the second rinse ingestion, the subjects should be instructed to drink additional water to bring the total volume ingested to 240 mL.
Study: NCT02181088

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 RH5 low dose
Description: ChAd63 RH5 at 5 x 10\^9 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 RH5 full dose
Description: ChAd63 RH5 at 5 x 10\^10 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 RH5 full dose
Description: ChAd63 RH5 at 5 x 10\^10 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 RH5 full dose
Description: ChAd63 RH5 at 5 x 10\^10 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA RH5 low dose
Description: MVA RH5 at 1 x 10\^8 pfu

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA RH5 full dose
Description: MVA RH5 at 2 x 10\^8 pfu
Study: NCT03270501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Axial spondyloarthritis patients who don't have a good treatment response on 2 NSAIDs, will be treated with golimumab. After remission, the therapy will be stopped.~All patients will undergo a ileocoloscopy at baseline and, if positive, at time of remission.
Study: NCT03980704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMPACT
Description: Administration of oral immunostimulating oral supplement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: resource protein
Description: Administration of oral high-protein oral supplement
Study: NCT02610114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Z-Score and computer algorithm
Description: In addition to the routine Z-score for zygote selection, if needed, the photographs of the zygotes already taken for quality and safety reasons are analysed using the new computer algorithm. Within a few minutes it generates a score, determining the quality of the cells. The two best cells upon Z-score result and new computer algorithm result are selected for first transfer.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Z-Score
Description: After fertilisation pronuclei and nucleoli can be seen inside the cells by microscope. Routinely, the alignment of nucleoli can be used generating a score, the Z-score 1-4, established by Scott. Two zygotes getting the best Z-score are selected for cell culture and the cells that develop to embryo stage are used for first transfer.
Study: NCT04097574

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NPO-13: l-menthol
Description: 20 mL/site

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPO-13: l-menthol
Description: 20 mL/site

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPO-13: l-menthol
Description: 20 mL/site
Study: NCT01223781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback-based motor learning for PD
Description: Prior to freezing episodes, auditory stimulation is triggered

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback-based motor learning for PD
Description: Prior to freezing episodes, auditory stimulation is triggered
Study: NCT02407600

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: FOSAPREPITANT (Emend)
Description: Uee of fosprepitant in EITHER first OR 2nd cycle of carboplatin containing combination chemotherapy in patients with advanced NSCLC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOSAPREPITANT (Emend)
Description: Uee of fosprepitant in EITHER first OR 2nd cycle of carboplatin containing combination chemotherapy in patients with advanced NSCLC

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT02395159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena™ IMS
Description: Prevena™ IMS is intended for the management of the surgical incision environment and surrounding healthy skin in patients with a risk of postoperative complications such as infections. This entails the maintenance of a closed environment around the incision by applying a negative pressure wound therapy system.~The corresponding dressing is known under the name Prevena™ Dressing. The layer closest to the skin comprises silver foil, which reduces the microbial colonisation of cells.

Intervention type: OTHER
Group type: OTHER
Intervention: sterile plaster dressings
Description: standard wound management method of sterile plaster dressings
Study: NCT02360878

Intervention type: DEVICE
Intervention: EndoBarrier Gastrointestinal Liner
Description: Implantation with the EndoBarrier

Intervention type: DEVICE
Intervention: EndoBarrier Gastrointestinal Liner
Description: Implantation with the EndoBarrier
Study: NCT01786577

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Both groups will undergo two MRIs at baseline and within 48 hours after surgery/non-surgery.

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Both groups will undergo two MRIs at baseline and within 48 hours after surgery/non-surgery.

Intervention type: BEHAVIORAL
Intervention: Cognitive assessment testing
Description: Both groups will undergo in-person baseline assessment of cognitive functioning as well as assessments at three weeks, three months and one year.

Intervention type: BEHAVIORAL
Intervention: Cognitive assessment testing
Description: Both groups will undergo in-person baseline assessment of cognitive functioning as well as assessments at three weeks, three months and one year.
Study: NCT02295618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard tracheal tube
Description: Intubation using Macintosh laryngoscope and standard tracheal tube

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard tracheal tube
Description: Intubation using Macintosh laryngoscope and standard tracheal tube

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETView VivaSight SL
Description: Intubation using ETView VivaSight SL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETView VivaSight SL
Description: Intubation using ETView VivaSight SL
Study: NCT01149018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol
Description: Oral solution of THC in concentration of 5mg/0.2ml. Dose regimen: 5mg 2-4 times/day as tolerated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally administered olive oil. Dose: 0.2ml 2-4 times a day as tolerated
Study: NCT04518358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of Expert Guiding Technology (GAINS) to Improve Live and Vocational Skills for Individuals with Developmental Challenges
Description: During the GAINS sessions, the Direct Support Professional (DSP) will follow the pre-programmed teaching protocol in the expert guiding technology. The system will provide step-by-step verbal prompts to the DSP throughout sessions. This includes which prompt to use for each step of the target skill, when to provide reinforcers, and which target task to work on. The system will also monitor the participant's (adults with ASD/ID) progress and notify the DSP if the target skill is mastered.
Study: NCT03131609

Intervention type: OTHER
Intervention: Container
Description: Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.

Intervention type: OTHER
Intervention: Container
Description: Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.

Intervention type: OTHER
Intervention: Silver Impregnated Wipe
Description: Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.

Intervention type: OTHER
Intervention: Silver Impregnated Wipe
Description: Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.

Intervention type: OTHER
Intervention: Funnel
Description: Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.

Intervention type: OTHER
Intervention: Funnel
Description: Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.

Intervention type: OTHER
Intervention: Castile-soap wipe
Description: Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.

Intervention type: OTHER
Intervention: Castile-soap wipe
Description: Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
Study: NCT01869764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02394587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction
Description: A non-pharmacological approach to pain management.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness-based Stress Reduction
Description: A non-pharmacological approach to pain management.
Study: NCT00965861

Intervention type: OTHER
Intervention: Tissue Registry Study
Description: If a patient consents to allowing the use of their tumor tissue sample(s) for testing/analysis at a future date, their name and information will be stored electronically in a registry that will be managed by SCRI. SCRI may then use the information contained in this registry (such as disease indication, demographic information, etc.) at any time in the future to select tissue samples on which to perform testing/analyses.
Study: NCT01614392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High velocity low force Power Training
Description: Lower Extremity high velocity power training performed at lower external resistance (40% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low velocity high force Power Training
Description: Lower extremity low velocity power training performed at high external resistance (70% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
Study: NCT04151576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy massage
Description: aromatherapy massage
Study: NCT01637441

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic sacropexy
Description: under laparoscopic vision, the vesico-vaginal space is dissected until the level of the bladder neck. a synthetic non absorbable mesh is placed between the bladder and the vagina. the mesh is sutured to the vagina and the apex (vaginal apex or uterus) and anchored to the prevertebral ligament in front of the promontorium.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vaginal mesh
Description: after anterior sagittal colpotomy, the bladder is dissected under the fascia layer, and the paravesical fossa are entered. a synthetic non absorbable mesh is placed with 4 arms suspension (trans obturator or not). treatment of the apex is mandatory.
Study: NCT00702299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: IP cisplatin will be administered on day 2 of each cycle at 75mg per m2 and IP paclitaxel will be administered at 60mg per m2 on day 8 of each cycle. Courses will be repeated every 21 days for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: IP cisplatin will be administered on day 2 of each cycle at 75mg per m2 and IP paclitaxel will be administered at 60mg per m2 on day 8 of each cycle. Courses will be repeated every 21 days for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Escalate doses in groups of 3 patients to 60mg per m2, 120 mg per m2, 500 mg per m2, 750 mg per m2, 1000 mg per m2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biologic sample preservation procedure
Description: Plasma samples will be collected on the 1st course at baseline, 30 minutes, 60 minutes, 2 hours, 4 hours, 6 hours (if possible) and 24 hours after the first IP Alimta® dose.
Study: NCT02851472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Description: Nitric oxide gas will be added to the inhaled gas mixture that the patient was already receiving at baseline, using standard of care gas delivery systems adapted specifically for this study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo gas (nitrogen) will be added to the inhaled gas mixture that the patient was already receiving at baseline, using standard of care gas delivery systems specifically adapted for this study.
Study: NCT01521403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 3x500 mg/day for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3x1 tablet per day for 10 days
Study: NCT03638037

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D measurement
Description: Maternal serum 25- hydroxyl vitamin D level

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D measurement
Description: Maternal serum 25- hydroxyl vitamin D level
Study: NCT04235621

Intervention type: OTHER
Intervention: FSGS/TR-MCD
Description: This is a non-interventional study

Intervention type: OTHER
Intervention: Diabetic Nephropathy (DN)
Description: This is a non-interventional study
Study: NCT00834093

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epstein-Barr Virus Specific Immunotherapy
Study: NCT01579929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225, Etoposide and Cisplatin
Description: In a standard, 3 + 3 dose escalation phase, two successive cohorts of ES-SCLC patients will receive LDE225 with etoposide and cisplatin with a dose of 200 mg to be reserved for de-escalation until the MTD is determined. Cohorts of at least 3 evaluable patients will be treated at each dose level of LDE225 (400 mg daily and 800 mg daily). One additional dose (200 mg daily) will be reserved for de-escalation. A minimum of 6 evaluable patients must be treated at the dose declared to be the MTD. Each cohort will consist of newly enrolled patients. An estimated total of 6 to 12 patients may be necessary to establish the MTD. Actual accrual will depend on the dose levels tested and the DLT observed. Upon completion of a minimum of four and a maximum of six cycles of LDE225 with etoposide and cisplatin, patients in each cohort with at least stable disease will receive maintenance LDE225 until disease progression or unacceptable toxicity.
Study: NCT00248768

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial magnetic Stimulator
Description: a device which produces intense magnetic fields in the brain and activates cerebral neurons
Study: NCT04071288

Intervention type: PROCEDURE
Intervention: total laparoscopic hysterectomy and simultaneous incontinence surgery with benign causes
Description: total laparoscopic hysterectomy and simultaneous incontinence surgery with benign causes; Burch colposuspension and mid-urethral sling operations for stress urinary incontinence

Intervention type: PROCEDURE
Intervention: total laparoscopic hysterectomy and simultaneous incontinence surgery with benign causes
Description: total laparoscopic hysterectomy and simultaneous incontinence surgery with benign causes; Burch colposuspension and mid-urethral sling operations for stress urinary incontinence
Study: NCT02964091

Intervention type: DRUG
Group type: OTHER
Intervention: sofosbuvir/ledipasvir
Study: NCT03193593

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo- Single injection of saline into Pectoralis Muscle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EB-001
Description: Single injection of EB-001 into Pectoralis Muscle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EB-001
Description: Single injection of EB-001 into Pectoralis Muscle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EB-001
Description: Single injection of EB-001 into Pectoralis Muscle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EB-001
Description: Single injection of EB-001 into Pectoralis Muscle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EB-001
Description: Single injection of EB-001 into Pectoralis Muscle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EB-001
Description: Single injection of EB-001 into Pectoralis Muscle
Study: NCT02864056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Ancient Chinese form of mind/body gentle exercise; this will be done while standing to improve postural balance.
Study: NCT03586466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BupreCare
Description: Subjects will receive their medication in a MedicaSafe device. Medication will be dispensed in accordance with the programmed treatment plan for each subject. Subjects will complete a Check-In remotely each week with their device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: Subjects will be given buprenorphine/naloxone as a component of Medication Assisted Treatment (MAT).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine/naloxone
Description: Subjects will be given buprenorphine/naloxone as a component of Medication Assisted Treatment (MAT).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine/naloxone
Description: Subjects will be given buprenorphine/naloxone as a component of Medication Assisted Treatment (MAT).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MEMS
Description: Subjects will receive their medication in a MEMS pill bottle.
Study: NCT02231359

Intervention type: DRUG
Intervention: Berodual® Respimat® solution for inhalation
Study: NCT00309348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly measurement of graft flow